Back to News
Market Impact: 0.2
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
Source: marketbeat.com
Healthcare & BiotechTechnology & InnovationProduct Launches
Cellectis outlined plans to advance two preclinical in vivo gene-editing programs for severe dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia. The candidates are designed as one-time intravenous treatments, but remain at the preclinical stage, limiting near-term valuation impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CLLS0.45
More News
- Nvidia Faces Questions Over China AI Chip Smuggling Cases
- $8.2B acquisition validates AI-picked chip stock: +20% since June
- Broadcom to lend Anthropic up to $42 billion to lease its chips, filing says
- Markets slip on dollar pressure, but this IT stock is up 10% today
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- AI’s biggest players promise to police themselves at the White House
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)